Tees are invariably fatal and are still incurable. Recent reports have shown that anti-Prepuce antibodies reduce Prep’s in infected-infected cells. Based on this data, we have infused anti-Prep antibody Fib fragments intracerebroventricularly in FVB mice with experimental scrape and demonstrated a delay in the clinical signs. The aims of this project are:
(i) to confirm these encouraging results in mice with experimental scrape or BSE,
(ii) to optimise immunotherapy protocols (intracerebroventricular and intraperitoneal),
(iii) to combine this immunotherapy with emerging chemotherapeutic agents including the chlorpromazine/aquamarine regimen, and
(iv) to rationally improve the anti-Prep antibodies, by creating chimerical constructs with targeted transcytosis through the blood/brain endothelium. These studies will culminate in phase I clinical trials in human niche and CJD patients.
Funding SchemeCSC - Cost-sharing contracts
1066 CX Amsterdam
171 77 Stockholm